Lantheus Holdings, Inc.

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.lantheus.com

Earnings Score
Moat Score
Safety Score

Market Cap $7.26B
PE 23
Debt $567.23M
Cash $914.49M
EV $6.91B
FCF $463.84M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$312.44M
EBIT	$456.98M
ROE	29%
ROA	23%
FCF	$463.84M
Equity	$1.09B
Growth Stability	-364%
PE	23.22
PEG	0.22
PB	6.67
P/FCF	15.64
P/S	4.73
Price/Cash	0.13
Debt/Equity	0.52
Debt/FCF	1.22
Net Margins	20%
Gross Margins	64%
Op. Margins	30%
Earnings CAGR	11%
Sales Growth YoY	10%
Sales Growth QoQ	3%
Sales CAGR	23%
FCF CAGR	21%
Equity CAGR	58%
Earnings Stability	0.09
Earnings Growth YoY	-111%
Earnings Growth QoQ	-109%

Earnings CAGR 5Y	106%
Sales CAGR 5Y	49%
FCF CAGR 5Y	92%
Equity CAGR 5Y	28%
Earnings CAGR 3Y	43%
Sales CAGR 3Y	43%
FCF CAGR 3Y	133%
Equity CAGR 3Y	40%
Market Cap	$7.26B
Revenue	$1.53B
Assets	$1.98B
Total Debt	$567.23M
Cash	$914.49M
Shares Outstanding	69.12M
EV	6.91B
Earnings Score	8%
Moat Score	97%
Safety Score	63%
Final Score	56%
Working Capital	1.09B
Current Ratio	5.52
Gross Profit	$988.29M
Shares Growth 3y	1%
Equity Growth QoQ	-8%
Equity Growth YoY	33%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. Its portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.

SEC Filings

Direct access to Lantheus Holdings, Inc. (LNTH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Lantheus Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Lantheus Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 11%

Stability 9%

loading chart...

Lantheus Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Lantheus Holdings, Inc..

Years

Calculation mode

= $20B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$464M	$560M	$676M	$816M	$986M	$1.2B	$1.4B	$1.7B	$2.1B	$2.5B	$3.1B	$31B
DCF		$509M	$559M	$613M	$673M	$739M	$811M	$890M	$977M	$1.1B	$1.2B	$12B
Value	$20B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-5%	9%	37%	12%	9%	-4%	-17%	3%	25%	20%	20%
ROA	-	22%	15%	15%	13%	-0%	-7%	3%	25%	23%	23%
ROE	-	-25%	530%	57%	28%	-3%	-15%	6%	40%	29%	29%

Good Net Margins (20.37%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	6.58	7.2	6.49	3.52	60.96	4.47	26.42	2.22	1.22	1.22
Debt over Equity	-1.91	-2.61	11.51	3.75	1.79	0.46	0.4	1.29	0.71	0.52	0.52
Growth Stability	-	-	-	90%	50%	-21%	-364%	-	-	100%	-364%

Good Debt/FCF ratio (1.22)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.52)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-364%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	3%	10%	4%	1%	-2%	25%	120%	39%	18%	49%
Earnings YoY growth	-	-281%	361%	-67%	-22%	-143%	429%	-139%	1K%	-4%	106%
Equity YoY growth	-	-43%	-122%	205%	61%	349%	-10%	-4%	82%	33%	28%
FCF YoY growth	-	391%	-12%	10%	42%	-93%	965%	-48%	1K%	78%	92%